Obstructive Sleep Apnoea: From pathogenesis to treatment: Current controversies and future directions.
Obstructive sleep apnoea (OSA) is a common disease, recognized as an independent risk factor for a range of clinical conditions, such as hypertension, stroke, depression and diabetes. Despite extensive research over the past two decades, the mechanistic links between OSA and other associated clinical conditions, including metabolic disorders and cardiovascular disease, remain unclear. Indeed, the pathogenesis of OSA itself remains incompletely understood. This review provides opinions from a number of leading experts on issues related to OSA and its pathogenesis, interaction with anaesthesia, metabolic consequences and comorbidities, cardiovascular disease, genetics, measurement and diagnosis, surgical treatment and pharmacotherapeutic targets.
Eastwood
Peter R
PR
West Australian Sleep Disorders Research Institute, Department of Pulmonary Physiology, Sir Charles Gairdner Hospital, Nedlands, WA 6009, Australia. peter.eastwood@health.wa.gov.au
Malhotra
Atul
A
Palmer
Lyle J
LJ
Kezirian
Eric J
EJ
Horner
Richard L
RL
Ip
Mary S
MS
Thurnheer
Robert
R
Antic
Nick A
NA
Hillman
David R
DR
D000758:Anesthesia; D002318:Cardiovascular Diseases / Q000453:epidemiology; D015897:Comorbidity; D003920:Diabetes Mellitus / Q000453:epidemiology; D005260:Female; D006801:Humans; D006973:Hypertension / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D020181:Sleep Apnea, Obstructive / Q000209:etiology* / Q000378:metabolism / Q000628:therapy*; D020521:Stroke / Q000453:epidemiology